{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:37:08Z","timestamp":1791110228529,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The decreasing <jats:italic>Helicobacter pylori<\/jats:italic> eradication rate is primarily attributed to antibiotic resistance, and further exacerbated by uniform drug administration disregarding a host\u2019s metabolic capability. Consequently, applying personalized treatment based on antibiotic resistance-associated variants and the host\u2019s metabolic phenotype can potentially increase the eradication rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A custom next-generation sequencing panel for personalized <jats:italic>H. pylori<\/jats:italic> eradication treatment (NGS-PHET) was designed which targeted the regions for amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin-resistance in <jats:italic>H. pylori<\/jats:italic> and human proton-pump inhibitor (PPI) metabolism. The libraries were constructed following customized methods and sequenced simultaneously. The customized framework criteria, grounded in previously reported antibiotic resistance associated variants and the host\u2019s PPI metabolism, was applied to the NGS-PHET results and suggested a personalized treatment for each subject, which was validated through each subject\u2019s actual eradication outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both previously reported and novel variants were identified from <jats:italic>H. pylori<\/jats:italic> sequencing results. Concurrently, five <jats:italic>CYP2C19<\/jats:italic> homozygous extensive metabolizers and three <jats:italic>CYP3A4<\/jats:italic> intermediate metabolizers were identified. Among the total of 12 subjects, clarithromycin triple therapy was suggested for five subjects, bismuth quadruple therapy was suggested for six subjects, and rifabutin triple therapy was suggested for one subject by following the customized framework criteria. The treatment suggestion for nine of the 12 subjects was consistent with the treatment that each subject achieved eradication with.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Applying the methodology using the NGS-PHET and customized framework helps to perform eradication treatment quickly and effectively in most patients with antibiotic-resistant <jats:italic>H. pylori<\/jats:italic> strains, and is also useful in research to find novel antibiotic-resistance candidates.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2024.1379790","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:10:23Z","timestamp":1724908223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species"],"prefix":"10.3389","volume":"14","author":[{"given":"Byung-Joo","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Eui","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/microorganisms12010222","article-title":"A contemporary perspective on pathogenesis, diagnosis and treatment strategies","volume":"12","author":"Ali","year":"2024","journal-title":"Microorganisms"},{"key":"B2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jac\/dkh125","article-title":"Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA","volume":"53","author":"Bauer","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"D41","DOI":"10.1093\/nar\/gkx1094","article-title":"GenBank","volume":"46","author":"Benson","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1093\/jac\/dkx320","article-title":"Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials","volume":"72","author":"Chen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1096\/fj.201900774R","article-title":"Molecular detection of H. pylori antibiotic-resistant genes and molecular docking analysis","volume":"34","author":"Chu","year":"2020","journal-title":"FASEB J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1128\/AAC.00594-16","article-title":"rRNA binding sites and the molecular mechanism of action of the tetracyclines","volume":"60","author":"Chukwudi","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/cpt.2321","article-title":"Pharmacogene variation consortium: A global resource and repository for pharmacogene variation","volume":"110","author":"Gaedigk","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1523-5378.2006.00398.x","article-title":"Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori","volume":"11","author":"Gerrits","year":"2006","journal-title":"Helicobacter"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/0091270003258170","article-title":"CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans","volume":"43","author":"Gonzalez","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/hel.12299","article-title":"Helicobacter pylori and antibiotic resistance, A continuing and intractable problem","volume":"21","author":"Hu","year":"2016","journal-title":"Helicobacter"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1053\/j.gastro.2021.07.012","article-title":"Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies","volume":"161","author":"Hulten","year":"2021","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/MCG.0b013e3181d04592","article-title":"Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea","volume":"44","author":"Hwang","year":"2010","journal-title":"J. Clin. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5009\/gnl20288","article-title":"Evidence-based guidelines for the treatment of","volume":"15","author":"Jung","year":"2021","journal-title":"Gut Liver"},{"key":"B15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3904\/kjim.2015.30.6.801","article-title":"Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/jgh.12607","article-title":"Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea revised edition","volume":"29","author":"Kim","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jmii.2022.07.006","article-title":"Multiple amino acid substitutions in penicillin-binding protein-1A confer amoxicillin resistance in refractory Helicobacter pylori infection","volume":"56","author":"Kuo","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1128\/AAC.47.7.2169-2178.2003","article-title":"High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori","volume":"47","author":"Kwon","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1128\/AAC.44.8.2133-2142.2000","article-title":"Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori","volume":"44","author":"Kwon","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1128\/AAC.45.9.2609-2615.2001","article-title":"DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates","volume":"45","author":"Kwon","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12592","article-title":"Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study","volume":"24","author":"Lee","year":"2019","journal-title":"Helicobacter"},{"key":"B22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-med-042220-020814","article-title":"Diagnosis and treatment of","volume":"73","author":"Lee","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","article-title":"Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea","volume":"15","author":"Lee","year":"2010","journal-title":"Helicobacter"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s10620-014-3093-7","article-title":"Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance","volume":"59","author":"Lee","year":"2014","journal-title":"Dig Dis. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/hel.12031","article-title":"Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012","volume":"18","author":"Lee","year":"2013","journal-title":"Helicobacter"},{"key":"B26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/jgh.13906","article-title":"rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes","volume":"33","author":"Lee","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1523-5378.2011.00840.x","article-title":"Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea","volume":"16","author":"Lee","year":"2011","journal-title":"Helicobacter"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.12659\/MSM.901514","article-title":"Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of helicobacter pylori","volume":"23","author":"Lin","year":"2017","journal-title":"Med. Sci. Monit"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.4269\/ajtmh.17-0478","article-title":"Point mutations at","volume":"98","author":"L\u00f3pez-Gasca","year":"2018","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1111\/febs.12020","article-title":"Structure of RdxA\u2013an oxygen-insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori","volume":"279","author":"Mart\u00ednez-J\u00falvez","year":"2012","journal-title":"FEBS J."},{"key":"B32","first-page":"169","article-title":"[Helicobacter pylori in peptic ulcer and gastric cancer]","volume":"22","author":"Matsukura","year":"1995","journal-title":"Gan To Kagaku Ryoho"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMcp1001110","article-title":"Clinical practice. Helicobacter pylori infection","volume":"362","author":"McColl","year":"2010","journal-title":"N Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ueg2.12473","article-title":"The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance","volume":"11","author":"Mommersteeg","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1128\/AAC.39.1.107","article-title":"Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori","volume":"39","author":"Moore","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/hel.12286","article-title":"Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation","volume":"21","author":"Mori","year":"2016","journal-title":"Helicobacter"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2014.00019","article-title":"Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing","volume":"1","author":"Nishizawa","year":"2014","journal-title":"Front. Mol. Biosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3164\/jcbn.08-220R","article-title":"Quinolone-based third-line therapy for helicobacter pylori eradication","volume":"44","author":"Nishizawa","year":"2009","journal-title":"J. Clin. Biochem. Nutr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/jac\/dkf140","article-title":"A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori","volume":"50","author":"Okamoto","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"B40","volume-title":"Online mendelian inheritance in man, OMIM\u00ae MIM number: {124010}: {10\/26\/2020}","year":"2019"},{"key":"B41","volume-title":"Online mendelian inheritance in man, OMIM\u00ae MIM number: {124020}: {07\/23\/2019}","year":"2019"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/emboj\/20.8.1829","article-title":"Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3","volume":"20","author":"Pioletti","year":"2001","journal-title":"EMBO J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.3748\/wjg.v25.i32.4629","article-title":"Review of current diagnostic methods and advances in","volume":"25","author":"Pohl","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1128\/AAC.00545-10","article-title":"Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates","volume":"55","author":"Qureshi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1348-0421.2007.tb03990.x","article-title":"Correlation between substitutions in penicillin-binding protein 1 and amoxicillin resistance in Helicobacter pylori","volume":"51","author":"Rimbara","year":"2007","journal-title":"Microbiol. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkn051","article-title":"Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori","volume":"61","author":"Rimbara","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in helicobacter pylori: A systematic review and meta-analysis in world health organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/hel.12279","article-title":"Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey","volume":"21","author":"Shin","year":"2016","journal-title":"Helicobacter"},{"key":"B49","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.meegid.2010.04.005","article-title":"Evolution of bacterial genes: evidences of positive Darwinian selection and fixation of base substitutions in virulence genes of Helicobacter pylori","volume":"10","author":"Torres-Morquecho","year":"2010","journal-title":"Infect. Genet. Evol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/biom12050691","article-title":"Biomarker characterization and prediction of virulence and antibiotic resistance from","volume":"12","author":"Vital","year":"2022","journal-title":"Biomolecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.femsim.2004.12.011","article-title":"Identification of Helicobacter pylori and the cagA genotype in gastric biopsies using highly sensitive real-time PCR as a new diagnostic tool","volume":"44","author":"Yamazaki","year":"2005","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/mdr.2015.0361","article-title":"Occurrence of mutations in the antimicrobial target genes related to levofloxacin, clarithromycin, and amoxicillin resistance in helicobacter pylori isolates from buenos aires city","volume":"23","author":"Zerbetto De Palma","year":"2017","journal-title":"Microb. Drug Resist."}],"updated-by":[{"DOI":"10.3389\/fcimb.2024.1502072","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000}}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1379790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:41:39Z","timestamp":1729849299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1379790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":53,"alternative-id":["10.3389\/fcimb.2024.1379790"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1379790","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fcimb.2024.1502072","asserted-by":"object"}]},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1379790"}}